The chronic high cholesterol market is set to hit $15.53 billion in 2032 across seven major markets, but the need for new drugs and controlled pricing will cause a major shake-up, according to a new GlobalData report.
The report found that the dyslipidemia market across the U.S., France, Germany, Italy, Spain, Japan and the U.K. will grow from $5.56 billion in 2022 to $15.53 billion in 2032. This, the analysts say, will be driven by the “launch of therapies with promising efficacies and new mechanism of actions” as well as the growth of the dyslipidemia population in general.
Dyslipidemia, where patients have chronically high unhealthy cholesterol levels, is also a major risk fact in several heart diseases.
GlobalData’s latest report sees eight late-stage pipeline therapies entering the market during the forecast period to 2032.
The analysts say the most significant driver of growth will be the launch of the new mechanism of action from NewAmsterdam Pharma’s cholesteryl ester transfer protein inhibitor obicetrapib, coupled with the anticipated launch of Merck’s first oral proprotein convertase subtilisin/kexin type 9 inhibitor and Akcea Therapeutics apoC-III antisense RNAi oligonucleotide, olezarsen.
“The particular areas of unmet need are the mixed dyslipidemia space and the statin-intolerant patient pool,” said Shireen Mohammad, Ph.D., cardiovascular and metabolic disorders analyst at GlobalData, in a release.
“These patients do not necessarily correspond to the high-risk atherosclerotic cardiovascular disease population, but they consist of large patient groups who most likely will not receive biologic-based therapies.”
Mohammad further explains that these patients are presently undergoing treatment with statins, ezetimibe and/or fibrates. However, he notes that the popularity of the fibrates drug class among physicians is diminishing, and he highlights that ezetimibe is not the most effective lipid-lowering therapy. He asserts that this underscores the evident need for improved dyslipidemia treatments.
“Overall, the dyslipidemia space is set to undergo a massive shake-up during the forecast period, not just in terms of market leaders, but also in how the disease is treated,” Mohammad concludes.
“Although the rise of novel, efficacious biologics has potential to improve prognosis and quality of life for dyslipidemia patients, these drugs will put a huge financial strain on healthcare systems across the seven major markets. Drug developers will need to carefully consider how they price their medications and which patients they will initially target to successfully penetrate the market.”